219: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 1

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.
In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.
Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.
In this episode, you’ll learn about:
• The historical and current challenges in characterizing these interactions at scale (06:22)
• How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)
• A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)
• The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)
• Real-world examples of how A-Alpha Bio’s approach is compressing years of work into months without sacrificing quality (13:58)
• The science behind A-Alpha Bio’s AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)
• The practical affinity range the technology can measure, covering most therapeutic applications (23:25)
Whether you’re a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.
Connect with Troy Lionberger:
LinkedIn: www.linkedin.com/in/troylionberger (linkedin.com/in/troylionberger)
A-Alpha Bio website: aalphabio.com/technology
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here (stan.store/SmartBiotech/p/ondemand-cmc-experti…)
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here (smartbiotechscientist.com/#cmc)
Support the show (buzzsprout.com/2263581/support)